



DECEMBER 5-9, 2023 | @SABCSSanAntonio

Primary Results From a Phase 2a Study of Zanidatamab in Combination With Palbociclib Plus Fulvestrant in HER2+ HR+ Metastatic Breast Cancer

Santiago Escrivá-de-Romani,^{1,*} Juan M. Cejalvo,² Emilio Alba,^{3,4} Jennifer Friedmann,⁵ Álvaro Rodríguez Lescure,⁶ Marie-France Savard,⁷ Rossanna C. Pezo,⁸ Maria Gion,⁹ Manuel Ruiz-Borrego,¹⁰ Erika Hamilton,¹¹ Timothy Pluard,¹² Marc Webster,¹³ Muralidhar Beeram,¹⁴ Hannah Linden,¹⁵ Cristina Saura,¹ Diana Shpektor,¹⁶ Bob Salim,¹⁷ Phoebe Harvey,¹⁷ Sara Hurvitz¹⁵

*Primary/Presenting Author


¹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain; ²Hospital Clínico Universitario de Valencia, Valencia, Spain; ³Hospital Regional Universitario y Virgen de la Victoria, Málaga, Andalucía, Spain; ⁴Centro de Investigación Biomédica en Red de Oncología, CIBERONC, Madrid, Spain; ⁵Jewish General Hospital, Montreal, QC, Canada; ⁶Hospital General Universitario de Elche, Elche, Alicante, Spain; ⁷The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; ⁸Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ⁹Hospital Ruber Internacional, Madrid, Spain, Hospital Universitario Ramón y Cajal, Madrid, Spain; ¹⁰Hospital Universitario Virgen del Rocio, Sevilla, Andalucía, Spain; ¹¹Sarah Cannon Research Institute (SCRI)/Tennessee Oncology, Nashville, TN, USA; ¹²Saint Luke's Cancer Institute, University of Missouri, Kansas City, MO, USA; ¹³Tom Baker Cancer Centre, Calgary, AB, Canada; ¹⁴South Texas Accelerated Research Therapeutics (START), San Antonio, TX, USA; ¹⁵University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA; ¹⁶Zymeworks Inc, Vancouver, BC, Canada; ¹⁷Jazz Pharmaceuticals, Palo Alto, CA, USA.

Disclosures

- **Consultant for:** AstraZeneca, COR2ED, Daiichi Sankyo, Pierre-Fabre, and Seagen
- Speaker's Bureau for: AstraZeneca, COR2ED, Daiichi Sankyo, Novartis, Pfizer, Roche, Seagen, and SOLTI
- Grant/Research support from: Byondis, Daiichi Sankyo, MEDSIR, Roche, SOLTI, Synthon, and Zymeworks
- Travel Grants from: Daiichi Sankyo, Kern, Pfizer, Seagen, and SOLTI
- Stockholder in: None
- Honoraria from: None

Background and Objective

- Prior studies with a HER2-targeting agent combined with an ER antagonist with or without a CDK 4/6 inhibitor have shown clinical benefit in patients with HER2+ HR+ mBC^{1,2}
- Zanidatamab is a bispecific antibody that simultaneously binds two non-overlapping extracellular domains of HER2 (biparatopic binding) leading to³:
 - Receptor crosslinking, clustering, internalization, and downregulation
 - Inhibition of tumor cell signaling and proliferation by preventing HER2 dimerization
 - Immune-mediated antitumor effects including antibodydependent cellular cytotoxicity and phagocytosis, and complement-dependent cytotoxicity




Objective: To evaluate the safety and efficacy of zanidatamab in combination with palbociclib (CDK4/6 inhibitor) plus fulvestrant (ER antagonist) in HER2+ HR+ mBC

1. Tolaney SM, et al. Lancet Oncol. 2020;21(6):763-775. 2. Ciruelos E, et al. Clin Cancer Res. 2020;26(22):5820-5829. 3. Weisser NE, et al. Nat Commun. 2023;14(1):1394.

This presentation is the intellectual property of the author/presenter. Contact them at sescriva@vhio.net for permission to reprint and/or distribute

Study Design: Phase 2a study (NCT04224272)



 Part 1 of the study evaluated safety and was previously reported (n=45); no zanidatamab-related DLTs occurred and the RDs for part 2 were identified^{1,c}

^aMandatory infusion-related reaction prophylaxis (acetaminophen, diphenhydramine, and corticosteroids [hydrocortisone or dexamethasone]). ^bAfter loading doses of 500 mg IM on days 1, 15, 28. ^cOne DLT of grade 4 neutropenia lasting >7 days occurred and was related to palbociclib. 1. Escrivá-de-Romani S, et al. Presented at San Antonio Breast Cancer Symposium 2022. Poster presentation [PD18-10].

This presentation is the intellectual property of the author/presenter. Contact them at sescrive @vhip.net for permission to reprint and/or distribute

Demographics and Baseline Characteristics

- Enrollment completed November 2022 (data extracted August 2023)
- HER2 central testing: 32 patients were HER2+ (ccHER2+), 18 HER2- (positive with local assessment), and 1 patient had missing data
- PAM50 subtyping: available for 29 patients (57%) who had adequate tissue samples

	All Patients (N=51)	ccHER2+ (n=32)	non-ccHER2+ (n=19)		All Patients (N=51)	ccHER2+ (n=32)	non-ccHER2+ (n=19)
Median age (range), years	54 (36-77)	55 (36-75)	54 (39-77)	Prior endocrine therapy: metastatic setting, n (%)	37 (73)	21 (66)	16 (84)
Female sex, n (%)	49 (96)	31 (97)	18 (95)	Median # of prior regimens (range)	1 (0-5)	1 (0-5)	1 (0-3)
Race, n (%)				Prior fulvestrant therapy: any setting, n (%)	11 (22)	6 (19)	5 (26)
White	42 (82)	30 (94)	12 (63)	Prior HER2-targeted therapy: any setting, n (%)	51 (100)	32 (100)	19 (100)
Asian	2 (4)	1 (3)	1 (5)	Median (range)	4 (2-6)	4 (1-10)	3 (2-8)
Other	7 (14)	1 (3)	6 (32)	Trastuzumab	51 (100)	32 (100)	19 (100)
ECOG PS, n (%)	()	(-)	- (-)	T-DM1	50 (98)	31 (97)	19 (100)
0	25 (49)	18 (56)	7 (37)	Pertuzumab	42 (82)	26 (81)	16 (84)
1	26 (51)	14 (44)	12 (63)	Lapatinib	14 (27)	9 (28)	5 (26)
HER2 and HR status: local testing, n (%)	51 (100)	. ,		Tucatinib	13 (25)	11 (34)	2 (11)
HER2+: central testing	32 (63)	32 (100)	0 (0)	T-DXd	12 (24)	8 (25)	4 (21)
HR+: local testing only	51 (100)	32 (100)	19 (100)	Neratinib	2 (4)	2 (6)	0 (0)
Prior history of brain metastases, n (%)	9 (18)	8 (25)	1 (5)	Margetuximab	1 (2)	1 (3)	0 (0)
Prior systemic anticancer therapy	51 (100)	32 (100)	19 (100)				
regimens: metastatic setting, n (%)							
Median # of prior regimens (range)	4 (1-12)	4 (1-12)	4 (2-10)				

This presentation is the intellectual property of the author/presenter. Contact them at sescriva@vhio.net for permission to reprint and/or distribute

Efficacy and Duration of Treatment

- Median (range) follow-up time: 16 (2-32) months
- Median (range) duration of zanidatamab treatment: 8 (1-30) months


	All Patients (N=51)	ccHER2+ Subset (n=32)	non-ccHER2+ Subset (n=19)
PFS6 , n (%) [95% CI]	34 (67) [52, 79]	22 (69) [50, 84]	12 (63) [38, 84]
Median PFS, months (95% CI)	12 (8, 15)	15 (9, 17)	8 (4, 9)
cORR, n (%) [95% CI]ª	16 (35) [21, 50]	14 (48) [29, 68]	2 (10) [1, 33]
cBOR, n (%)ª			
CR	3 (6)	3 (10)	0 (0)
PR	13 (28)	11 (38)	2 (12)
SD	26 (56)	13 (45)	13 (76)
PD	4 (9)	2 (7)	2 (12)
DCR, n (%) [95% CI]	42 (91) [79, 98]	27 (93) [77, 99]	15 (88) [64, 98]
Median DOR, months (95% CI) ^b	15 (12, 25)	14 (11, 25)	NE (7, NE) ^c

^aEvaluated in patients with measurable disease (n=46 all patients; n=29 ccHER2+ subset; n=17 non-ccHER2+ subset. ^bEvaluated in patients with a CR or PR (n=16 all patients; n=14 ccHER2+ subset; n=2 non-ccHER2+ subset). ^cMedian DOR was 7.1 and 24.1 months for the 2 patients with a response in the non-ccHER2+ subset.

This presentation is the intellectual property of the author/presenter. Contact them at sescriva@uhio.net for permission to reprint and/or distribute

San Antonio Breast Cancer Symposium®, December 5-9, 2023

Efficacy of Treatment by Best Overall Response (All Patients With Measurable Disease)




*Indicates patients with unconfirmed partial responses. Dotted lines indicate -30% and +20% change in tumor size.

^aAll patients received prior trastuzumab and taxane.

This presentation is the intellectual property of the author/presenter. Contact them at sescriva@uhio.net for permission to reprint and/or distribute

Treatment Duration and PFS



This presentation is the intellectual property of the author/presenter. Contact them at sescriva@vhio.net for permission to reprint and/or distribute

Efficacy of Treatment by PAM50 Subtype

	All Patients With PAM50 Subtyping (n=29)	Basal-Like (n=1)ª	HER2-Enriched (n=16)	Luminal B (n=12)
PFS6 , n (%) [95% CI]	19 (66) [46, 82]	1 (100) [2, 100]	10 (62) [35, 85]	8 (67) [35, 90]
Median PFS, months (95% CI)	9 (7, 14)	6 (NE, NE)	9 (4, 15)	12 (3, 24)
cORR, n (%) ^b	7 (28)	0	4 (27)	3 (30)
cBOR, n (%) ^b				
CR	1 (4)	0	1 (7)	0
PR	6 (24)	0	3 (20)	3 (30)
SD	16 (64)	0	10 (67)	6 (60)
PD	2 (8)	0	1 (7)	1 (10)
DCR, n (%) [95% Cl] ^b	23 (92) [74, 99]	0	14 (93) [68, 100]	9 (90) [56, 100]
Median DOR, months (95% CI) ^c	22 (12, NE)	0	13 (12, NE)	NE (22, NE)

20/

- Compared with HER2-enriched, luminal B mBC was associated with numerically, but not statistically significant, longer median PFS (12 vs 9 months; P=0.74) and similar PFS6 (67% vs 62%)
- The cORRs for patients with HER2-enriched or luminal B mBC were numerically similar

^aThis patient did not have measurable disease. ^bEvaluated in patients with measurable disease (n=25 all patients with PAM50 subtyping; n=15 HER2-enriched; n=10 luminal B). ^cEvaluated in patients with CR or PR (n=7 all patients with PAM50 subtyping; n=4 HER2-enriched; n=3 luminal B).

This presentation is the intellectual property of the author/presenter. Contact them at sescriva@uhio.net for permission to reprint and/or distribute

Safety Outcomes Following Treatment (All Patients)

	Patients (N=51)				
	Any Grade	Grade 3 or 4			
Any TRAE, n (%)	51 (100)	34 (67)			
Serious TRAE, n (%)	1 (2)	1 (2)			
TRAE in >20% of patients and/or grade 3 TRAE in ≥2 patients, n (%)					
Diarrhea	41 (80)	7 (14)			
Nausea	20 (39)	1 (2)			
Stomatitis	19 (37)	1 (2)			
Neutrophil count decreased/neutropenia	30 (59)	27 (53)			
Anemia	15 (29)	5 (10)			
Vomiting	13 (25)	1 (2)			
Asthenia	12 (24)	0 (0)			
Thrombocytopenia	8 (16)	3 (6)			
Hypomagnesemia	5 (10)	2 (4)			
Hypokalemia	4 (8)	2 (4)			
Treatment-related AESI, n (%)					
Ejection fraction decreased	6 (12)	1 (2) ^a			
Infusion-related reaction	2 (4)	0 (0)			

AEs requiring discontinuation of drug

- All treatments: 1 patient (grade 1 asthenia)
- Palbociclib treatment: 2 patients (1 had grade 3 diarrhea and 1 had grade 3 transaminases increased)

One serious TRAE (transaminases increased) was reported (event resolved)

AEs led to a dose reduction of zanidatamab in 4 patients

14 deaths (none related to treatment)

- 12 due to disease progression
- 1 due to an unrelated TEAE of COVID-19
- 1 cause unknown (causality pending)

^aEvent ongoing at the time data was extracted.

Conclusions

- Zanidatamab in combination with palbociclib plus fulvestrant demonstrated promising PFS outcomes (PFS6 of 67% and median PFS of 12 months) with durable responses (median DOR of 15 months) in this heavily-pretreated population
 - This trial is ongoing and OS data were not mature at data cutoff
 - There were no statistical differences in efficacy observed between luminal B and HER2-enriched subtypes
- This combination therapy was well tolerated with an easily manageable safety profile in heavily-pretreated patients with HER2+ HR+ mBC
- These results support further development of this novel chemotherapy-free treatment regimen for heavily-pretreated patients with HER2+ HR+ mBC

Funding and Acknowledgements

Funding

This study was sponsored by Zymeworks Inc., Jazz Pharmaceuticals, and Pfizer Inc.

Acknowledgments

We sincerely thank all patients and their families. We thank all the investigators, clinical study researchers, personnel, and staff who contributed to the study. Medical writing support, under the direction of the authors, was provided by CMC Affinity, a division of IPG Health Medical Communications, with funding from Jazz Pharmaceuticals, in accordance with Good Publication Practice (GPP 2022) guidelines